

Requested by Senator HAYDEN

**PROPOSED AMENDMENTS TO
SENATE BILL 598**

1 On page 1 of the printed bill, delete lines 6 through 27 and insert:

2 **“SECTION 2. (1) As used in this section:**

3 **“(a) ‘Authorized generic drug’ has the meaning given that term in**
4 **42 C.F.R. 447.502.**

5 **“(b) ‘Health care coverage’ has the meaning given that term in ORS**
6 **743B.602.**

7 **“(c) ‘Noninnovator multiple source drug’ has the meaning given**
8 **that term in 42 C.F.R. 447.502.**

9 **“(d) ‘Step therapy’ has the meaning given that term in ORS**
10 **743B.001.**

11 **“(e) ‘Utilization review’ has the meaning given that term in ORS**
12 **743B.001.**

13 **“(2) An entity that provides health care coverage for prescription**
14 **drugs shall ensure that:**

15 **“(a) The utilization review requirements, including step therapy, for**
16 **an authorized generic drug that is a noninnovator multiple source and**
17 **nonopioid drug prescribed for the treatment of chronic or acute pain**
18 **that is approved by the United States Food and Drug Administration**
19 **for the treatment of chronic or acute pain are no more restrictive than**
20 **the least restrictive utilization review requirements for opioid drugs**
21 **prescribed for the treatment of chronic or acute pain; and**

1 **“(b) The cost-sharing, copayment or deductible for an authorized**
2 **generic drug that is a noninnovator multiple source and nonopioid**
3 **drug prescribed for the treatment of chronic or acute pain is no**
4 **greater than the cost-sharing, copayment or deductible for an opioid**
5 **drug prescribed for the treatment of chronic or acute pain.**

6 **“SECTION 3. (1) As used in this section:**

7 **“(a) ‘Authorized generic drug’ and ‘noninnovator multiple source**
8 **drug’ have the meanings given those terms in 42 C.F.R. 447.502.**

9 **“(b) ‘Step therapy’ has the meaning given that term in ORS**
10 **743B.001.**

11 **“(c) ‘Utilization review’ has the meaning given that term in**
12 **743B.001.**

13 **“(2) Notwithstanding ORS 414.325 (5), the Oregon Health Authority**
14 **and a coordinated care organization shall ensure that the utilization**
15 **review requirements, including step therapy, for an authorized generic**
16 **drug that is a noninnovator multiple source and nonopioid drug pre-**
17 **scribed for the treatment of chronic or acute pain that is approved by**
18 **the United States Food and Drug Administration for the treatment of**
19 **chronic or acute pain are no more restrictive than the least restrictive**
20 **utilization review requirements for opioid drugs prescribed for the**
21 **treatment of chronic or acute pain.”.**

22
